IVIG, rituximab and monoclonal antibodies are increasingly discussed as possible Long Covid treatments. Here is what the evidence shows, why access remains difficult and what researchers still do not know.
IVIG, rituximab and monoclonal antibodies are increasingly discussed as possible Long Covid treatments. Here is what the evidence shows, why access remains difficult and what researchers still do not know.